PTGS2 and breast carcinoma: Higher rates of COX-2 expression in in situ compared with invasive tumors have led investigators to suggest that the potential therapeutic impact of COX-2 inhibition may be more relevant for in situ breast cancer than invasive breast cancer (reviewed in [48]).